Role of Alanine Racemase Mutations in Mycobacterium tuberculosis d -Cycloserine Resistance
Author(s) -
Yoshio Nakatani,
Helen K. OpelReading,
Matthias Merker,
Diana Machado,
Sönke Andres,
S Siva Kumar,
Danesh Moradigaravand,
Francesc Coll,
João Perdigão,
Isabel Portugal,
Thomas Schön,
Diir,
Kangjam Rekha Devi,
Thomas A. Kohl,
Patrick Beckert,
Taane G. Clark,
Gugu Maphalala,
Derrick Khumalo,
Roland Diel,
Kadri Klaos,
Htin Aung,
Gregory M. Cook,
Julian Parkhill,
Sharon J. Peacock,
Soumya Swaminathan,
Miguel Viveiros,
Stefan Niemann,
Kurt L. Krause,
Claudio U. Köser
Publication year - 2017
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01575-17
Subject(s) - cycloserine , mycobacterium tuberculosis , microbiology and biotechnology , biology , mutation , drug resistance , in vitro , alanine , tuberculosis , genetics , antibiotics , gene , amino acid , medicine , pathology
A screening of more than 1,500 drug-resistant strains of Mycobacterium tuberculosis revealed evolutionary patterns characteristic of positive selection for three alanine racemase (Alr) mutations. We investigated these mutations using molecular modeling, in vitro MIC testing, as well as direct measurements of enzymatic activity, which demonstrated that these mutations likely confer resistance to d-cycloserine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom